Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Kell

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Expert Opinion on Emerging Drugs|May 25, 2004
Emerging treatments in acute myeloid leukaemiaJonathan Kell
Reviews on Recent Clinical Trials|May 14, 2008
Treatment of relapsed acute myeloid leukaemiaJonathan Kell
Expert Review of Anticancer Therapy|March 5, 2016
The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemiaJonathan Kell
Leukemia Research|July 3, 2016
Considerations and challenges for patients with refractory and relapsed acute myeloid leukaemiaJonathan Kell
Current Opinion in Investigational Drugs (London, England : 2000)|July 12, 2007
Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancerJonathan Kell
Drugs of Today (Barcelona, Spain : 1998)|January 5, 2008
Tipifarnib in acute myeloid leukemiaAlan K Burnett, Jonathan Kell
European Journal of Haematology|November 15, 2002
Retinoid-induced apoptosis in B-cell chronic lymphocytic leukaemia cells is mediated through caspase-3 activation and is independent of p53, the retinoic acid receptor, and differentiationChris Pepper, Khalida Ali, Alun Thomas, et al.
British Journal of Haematology|May 30, 2012
The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AMLAlan K Burnett, Nigel H Russell, Dominic Culligan, et al.
Haematologica|February 28, 2016
Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 TrialAlan Burnett, Jamie Cavenagh, Nigel Russell, et al.
Blood|July 22, 2006
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapySteven Knapper, Alan K Burnett, Tim Littlewood, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Expert Opinion on Emerging Drugs|May 25, 2004
Emerging treatments in acute myeloid leukaemiaJonathan Kell
Reviews on Recent Clinical Trials|May 14, 2008
Treatment of relapsed acute myeloid leukaemiaJonathan Kell
Expert Review of Anticancer Therapy|March 5, 2016
The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemiaJonathan Kell
Leukemia Research|July 3, 2016
Considerations and challenges for patients with refractory and relapsed acute myeloid leukaemiaJonathan Kell
Current Opinion in Investigational Drugs (London, England : 2000)|July 12, 2007
Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancerJonathan Kell
Drugs of Today (Barcelona, Spain : 1998)|January 5, 2008
Tipifarnib in acute myeloid leukemiaAlan K Burnett, Jonathan Kell
European Journal of Haematology|November 15, 2002
Retinoid-induced apoptosis in B-cell chronic lymphocytic leukaemia cells is mediated through caspase-3 activation and is independent of p53, the retinoic acid receptor, and differentiationChris Pepper, Khalida Ali, Alun Thomas, et al.
British Journal of Haematology|May 30, 2012
The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AMLAlan K Burnett, Nigel H Russell, Dominic Culligan, et al.
Haematologica|February 28, 2016
Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 TrialAlan Burnett, Jamie Cavenagh, Nigel Russell, et al.
Blood|July 22, 2006
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapySteven Knapper, Alan K Burnett, Tim Littlewood, et al.
Pageof 3